Clinical trials: Mucosal Immunity
Shigella
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
- Trial name
- NCT00866476
- Testing
- CVD 1208S, a Shigella flexneri 2a live, oral vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
COPD
Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)
This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms…
- Trial name
- NCT04901455
- Testing
- LAIV
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV-1 Infection, HIV Reservoir
Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy
The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART).
- Conditions
- HIV-1 Infection, HIV Reservoir, Antiretroviral Therapy
- Trial name
- ANRSGALT-2 (NCT07656077)
- Testing
- Colonic Mucosal Biopsies
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Cystic Fibrosis
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis
This project entitled "Impaired secretory IgA and mucosal immunity in cystic fibrosis" is a research program which aims to determine, owing to national (KULeuven) and international (Descartes university Paris, university of…
- Trial name
- Forton2015 (NCT02308267)
- Testing
- Lung explants, Sputum, nasal fluid and serum, Bronchoscopy
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Impact of Vaccination
Intranasal LAIV Mucosal Immunity Examination
The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines.
- Trial name
- NCT07093281
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA)
Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives
The investigators are conducting a research study to understand how cells responsible for fighting infection (immune cells) are affected by hormonal contraceptive use.
- Conditions
- Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
- Trial name
- NCT01750476
- Testing
- Mirena, Oral contraception, Depo-Provera
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Thomas Cherpes, DVM, MD
Irritable Bowel Syndrome
Manipulation of Visceral Sensitivity and Immune System in IBS
Irritable bowel syndrome (IBS) is a common condition. At least 20% of the population suffer from IBS. The symptoms of abdominal pain, diarrhoea, constipation, bloating and difficulty with bowel motions are often disabling.
- Trial name
- NCT00418340
- Testing
- probiotic (bacterial/dietary supplement)
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- London North West Healthcare NHS Trust
Typhoid Fever, Paratyphoid Fever
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
Enteric fever, an infection characterised by diarrhoea and rash, is most often caused by a bacteria called Salmonella enterica. After ingesting contaminated food or drink, the Salmonellae travel first to the gut, then the…
- Trial name
- NCT02192008
- Testing
- Salmonella Typhi, Salmonella Paratyphi
- Where
- United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Respiratory Tract Infections, Cold Symptoms
Beetroot Juice NO Cold Study
Currently, there is a lack of evidence-based prevention strategies for respiratory infection and management of these conditions can be costly to the public.
- Conditions
- Respiratory Tract Infections, Cold Symptoms, Exhaled Nitric Oxide
- Trial name
- NCS (NCT06416228)
- Testing
- Beetroot juice
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Southern Methodist University
Mumps, Measles
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
The purpose of this study is to investigate the immunity of persons fully vaccinated against measles, mumps and rubella and to examine the course of immunity after booster vaccination.
- Conditions
- Mumps, Measles, Rubella
- Trial name
- MIPS (NCT05894395)
- Testing
- MMR booster vaccination (as M-M-R-VaxPro)
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Zurich
COVID-19, SARS-CoV-2 Viraemia
Neutralizing Power of Serum Antibodies - 2
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies.
- Conditions
- COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination
- Trial name
- PNAS-2 (NCT07085611)
- Testing
- Sample collection (blood and optional nasal swab)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
COVID 19, Respiratory Synctial Virus
COMMUNITY - the COVID-19 Immunity Study
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients.
- Conditions
- COVID 19, Respiratory Synctial Virus, Influenza Virus, SARS-CoV-2 Virus
- Trial name
- COMMUNITY (NCT06784739)
- Testing
- Blood sampling, Mucosal sampling, PCR-test
- Where
- 2 sites in Sweden
- Volunteers
- 2,420 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Immunity, Mucosal, Immune System Processes
VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
Background: The Vaccine Research Center (VRC) is dedicated to understanding immune responses associated with prevention and treatment of infectious diseases.
- Conditions
- Immunity, Mucosal, Immune System Processes, Blood Specimen Collection
- Trial name
- NCT01132859
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Microbial Colonization
Role of the Oral Microbiome & Mucosal Immunity in COVID-19 Disease
Determining whether in the mouth there are differences between the participant groups in the nature and activity of mucosal innate immunity, in immune responses to SARS-COV2 antigens, or in the oral microbiome
- Conditions
- COVID-19, Microbial Colonization, Oral Disease, Periodontal Diseases
- Trial name
- MIMSA (NCT05212766)
- Testing
- COVID infection, COVID vaccination, Oral examination
- Where
- United Kingdom
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- King's College London
HIV
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and…
- Trial name
- MIP (NCT02333045)
- Testing
- Truvada qd, Maraviroc 300 qd
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections
A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
To compare the safety of ALVAC-HIV vCP205 to that of ALVAC-RG vCP65 rabies glycoprotein, delivered by a variety of mucosal routes. To evaluate the antibody, humoral, and cellular immune responses resulting from ALVAC-HIV vCP205.
- Trial name
- NCT00000884
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65)
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Intraepithelial Neoplasia
The Dynamic Process of VMB and Mucosal Immunity After FUS Treatment of CIN Patients With Fertility Requirement
Cervical cancer is the fourth leading cause of cancer death in women worldwide, and cervical intraepithelial neoplasia (CIN) can progress to cervical cancer.
- Trial name
- NCT05142397
- Testing
- Focused Ultrasound
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shufang Chang
HIV Infection
Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant
HIV-specific cellular immunity is hampered in most HIV-infected individuals. Therapeutic immunization in HIV aims to strengthen the HIV-specific cellular immunity, usually in the absence of replicating HIV with antiretroviral…
- Trial name
- NCT01473810
- Testing
- Vacc-4x low dose, Vacc-4x medium dose, Vacc-4x high dose
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Oslo University Hospital
Normal Physiology
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
Background: One form of the influenza vaccine is a nasal spray. It uses a live but weakened flu virus. Researchers want to better under how the live vaccine interacts with the body s immune system.
- Trial name
- NCT01730144
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)